Article summary
The Medicines and Healthcare products Regulatory Agency (MHRA) has published its Corporate Plan for 2023–2026 and its Business Plan for 2023–2024 outlining the MHRA’s direction over the next three years. MHRA’s focus is on keeping patients safe and enabling access to high quality, safe and effective medical products. The contents of the plans include the priority actions and activities which the MHRA will take going forward to maintain delivery of the statutory role and functions of the agency.
To continue reading this news article, as well as thousands of others like it, sign in with LexisNexis or register for a free trial